← Every company
Moderna Inc Patents
What Moderna Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
MRNA on carbonthat →Filings on file
13
Granted
0
Still pending
13
Filed under
2 names
13 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOFA61K 38/193, A61P 37/00, A61P 43/00, A61P 3/00, A61K 31/395, A61K 31/495, A61K 31/7088, A61K 31/7115, A61K 38/00, A61K 38/13, A61K 38/195, A61K 38/28, A61K 39/3955, A61K 48/00, A61K 48/0066, A61K 48/0075, A61K 48/0083, C07K 14/62, C07K 14/685, A61K2300/00Filed as Moderna TX, Inc.2025-08-29Jason P. Schrum | pending |
| HEPATITIS B VIRUS MRNA VACCINESFiled as Moderna TX, Inc.2025-03-12Anthony T. DiPiazza | pending |
| POLYNUCLEOTIDES ENCODING URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1 FOR THE TREATMENT OF CRIGLER-NAJJAR SYNDROMEA61K 48/0041, A61K 9/0021, A61K 9/08, A61K 9/127, A61K 9/5123, A61K 48/0066, C12N 9/1051, C12Y 204/01017Filed as Moderna TX, Inc.2025-01-23Paolo G. V. Martini | pending |
| ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOFFiled as Moderna TX, Inc.2025-01-10Jason P. SCHRUM | pending |
| Method for Replicating or Amplifying Circular DNAC12P 19/34, C12N 15/10Filed as Moderna Enzymatics Co., Ltd.2024-10-20Masayuki Suetsugu | pending |
| Method of Amplifying Circular DNAC12Q 1/6855, C12N 15/09, C12P 19/34, C12Q 1/6844, C12Q 1/686, C12Q2521/101, C12Q2521/319, C12Q2521/327, C12Q2521/501, C12Q2521/513, C12Q2521/519, C12Q2522/101, C12Q2525/307, C12Q2527/101, C12Q2527/125, C12Q2531/10, C12Q2563/159, C12Y 301/04001, C12Y 306/04012Filed as Moderna Enzymatics Co., Ltd.2024-10-20Masayuki Suetsugu | pending |
| Method for Producing Double-Stranded DNA Molecules Having Reduced Sequence ErrorsC12P 19/34, C12N 9/16, C12N 9/22, C12N 15/11, C12Q 1/6844Filed as Moderna Enzymatics Co., Ltd.2024-09-18Masayuki Suetsugu | pending |
| MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOFFiled as Moderna TX, Inc.2024-08-29Antonin DE FOUGEROLLES | pending |
| Functional DNA Cassette and PlasmidC12N 15/70, C12P 19/34Filed as Moderna Enzymatics Co., Ltd.2024-07-02Masayuki Suetsugu | pending |
| MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASEA61K 48/0066, C12N 15/85, A61K 47/543, A61P 7/06, A61P 25/14, A61P 27/02, A61P 37/00, A61P 7/00, A61P 7/02, A61P 17/06, A61P 17/08, A61P 21/00, A61P 21/04, A61P 37/02, A61P 7/04, A61P 9/10, A61P 19/00, A61P 25/28, A61P 25/30, A61P 31/00, A61P 43/00, A61P 3/00, A61P 9/00, A61P 17/14, A61P 25/02, A61P 31/12, A61P 37/06, A61P 3/06, A61P 17/00, A61P 19/02, A61P 31/14, A61P 31/18, A61P 35/02, A61P 37/08, Y02A 50/30, A61P 3/10, A61P 13/12, A61P 17/02, A61P 25/18, A61P 25/24, A61P 31/04, A61P 1/00, A61P 5/00, A61P 11/00, A61P 15/00, A61P 25/00, A61P 29/00, A61P 35/04, A61P 1/04, A61P 13/00, A61P 17/04, A61P 19/10, A61P 31/10, A61P 35/00, A61K 9/0019, A61K 9/1271, A61K 9/145, A61K 9/5123, A61K 9/5146, A61K 9/5153, A61K 31/7115, A61K 38/00, A61K 38/17, A61K 38/177, A61K 38/1816, A61K 38/1891, A61K 38/191, A61K 38/193, A61K 38/212, A61K 38/45, A61K 38/4846, A61K 48/0033, A61K 48/0041, A61K 48/005, A61K 48/0075, C07H 21/02, C07K 14/005, C07K 14/435, C07K 14/43595, C07K 14/47, C07K 14/4705, C07K 14/4713, C07K 14/4723, C07K 14/4746, C07K 14/475, C07K 14/485, C07K 14/495, C07K 14/505, C07K 14/515, C07K 14/525, C07K 14/535, C07K 14/5418, C07K 14/56, C07K 14/61, C07K 14/62, C07K 14/705, C07K 14/745, C07K 16/00, C07K 16/2863, C07K 16/2887, C07K 16/40, C12N 9/0069, C12N 9/0091, C12N 9/1051, C12N 9/1241, C12N 9/16, C12N 9/2402, C12N 9/2445, C12N 9/6435, C12N 9/6437, C12N 9/644, C12N 9/6443, C12N 9/6451, C12N 9/88, C12N 9/93, C12N 15/11, C12N 15/52, C12N 15/87, C12N 15/88, C12P 13/04, C12P 21/00, C12P 21/005, C12Y 113/12007, C12Y 116/03001, C12Y 207/07012, C12Y 304/21007, C12Y 304/21022, C12Y 304/21027, C12Y 403/02001, C12Y 603/02019Filed as Moderna TX, Inc.2024-07-01Antonin DE FOUGEROLLES | pending |
| Method for Producing Circular DNAC12P 19/34, C12N 9/1205, C12N 9/1217, C12N 9/1223, C12N 9/1229, C12N 15/10, C12N 15/11, C12Y 207/0104, C12Y 207/02001, C12Y 207/03002, C12Y 207/04001, C12Y 207/04006Filed as Moderna Enzymatics Co., Ltd.2024-02-21Masayuki Suetsugu | pending |
| SYNTHETIC NUCLEIC ACIDS AND METHODS OF USING THE SAME FOR IMPROVED POLYPEPTIDE PRODUCTIONFiled as Moderna TX, Inc.2024-02-14Edward John Miracco | pending |
| MRNAS ENCODING CHIMERIC METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOFC12N 9/0069, C12N 15/88, A61P 37/06, A61K 9/5123, A61K 48/005, C07K2319/033, C12N2800/22, C12Y 113/11011, C12Y 113/11052Filed as Moderna TX, Inc.2024-02-02Laurie Kenney | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on MRNA
Company overviewEverything on MRNA in one place, with the price.SEC filingsWhat MRNA's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat MRNA's own officers and directors buy and sell.Planned salesSales MRNA insiders have filed notice of.Who owns itEvery manager reporting a position in MRNA.Funds holding itWhich funds and ETFs hold MRNA, and how big a bet.LobbyingWhat MRNA spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on MRNA's account, and who they worked for.Federal contractsWhat federal agencies pay MRNA.